To read the full story, subscribe or sign in.

CBMG bags $120M in its first financing since going private, funds to benefit CAR T candidates

Oct. 5, 2021

Cell therapy developer Cellular Biomedicine Group Inc. (CBMG) completed a $120 million series A financing, its first since becoming a private company. The funds will benefit the U.S. and China-based firm’s CAR T pipeline.

BioWorld Asia Financings Cancer CAR T Series A China

Today's news in brief

BioWorld

BioWorld briefs for Sept. 18, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Sept. 18, 2025.

Health professional pointing stethoscope at Clinical Trial words, icons

‘Prolific’ Regeneron won’t stop with phase III FOP data drop

BioWorld

“People have some inability to focus on [Regeneron Pharmaceuticals Inc.’s] pipeline,” which stands as “the most prolific in the industry, I would dare to say,”...

The ‘molecular revolution’ driving R&D of new cancer therapeutics

BioWorld Asia

“New explosions in biotechnology are allowing us to interrogate cancers at a very sophisticated level compared to before,” Dennis Slamon told audience members at...

Elderly woman holding illustration of brain with missing puzzle piece

Remynd’s REM-127 yields positive phase II data in Alzheimer’s

BioWorld

Remynd NV has turned in positive phase IIa data for a new target in Alzheimer’s disease, showing that restoring calcium homeostasis in neurons reduces levels of...